Targeted Therapy in Patients with Metastatic Male Germ Cell Tumors

Urol Int. 2021;105(7-8):720-723. doi: 10.1159/000510717. Epub 2021 Mar 17.

Abstract

Ten to fifteen percent of patients with metastatic testis cancer (mGCT) will develop chemorefractory disease of which about 50% will die. We report on the integration of next generation sequencing in daily clinical practice to identify druggable mutations in metastatic lesions of 3 patients with mGCT. Mutational analysis revealed KIT D820G, TP53, and NPM1 mutations as well as mismatch repair deficiency with loss of MSH2 and MSH6 proteins so that targeted therapy with sunitinib (n = 2) or pembrolizumab (n = 1) was initiated resulting in remarkable partial remissions for 9, 12+, and 15 months.

Keywords: Chemotherapy; Druggable mutations; Next generation sequencing; Testicular cancer.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Aged
  • Humans
  • Male
  • Neoplasm Metastasis
  • Neoplasms, Germ Cell and Embryonal / drug therapy*
  • Neoplasms, Germ Cell and Embryonal / pathology
  • Testicular Neoplasms / drug therapy*
  • Testicular Neoplasms / pathology

Supplementary concepts

  • Male Germ Cell Tumor